基于高通量测序筛选骨质疏松大鼠差异circRNA及其功能验证的研究

黄环, 孙荣鑫, 张磊, 史易晗, 吴萍

【作者机构】 新疆医科大学第六附属医院关节外科
【分 类 号】 R363.2
【基    金】 新疆维吾尔自治区卫生健康保健科研专项项目(BH202431)。
全文 文内图表 参考文献 出版信息
基于高通量测序筛选骨质疏松大鼠差异circRNA及其功能验证的研究

基于高通量测序筛选骨质疏松大鼠差异circRNA及其功能验证的研究

黄 环 孙荣鑫 张 磊 史易晗 吴 萍

新疆医科大学第六附属医院关节外科,新疆乌鲁木齐 830002

[摘要] 目的 筛选骨质疏松大鼠模型中差异表达的环状RNAs(circRNAs),探讨circRNA在骨质疏松发病中的作用及作为潜在治疗靶点的可能性。 方法 12只8周龄SPF级雌性SD大鼠采用随机数字表法分为假手术组和去卵巢组,每组6只。建模后12周,取股骨骨组织,高通量测序筛选差异circRNAs;在骨髓间充质干细胞(BMSCs)中过表达及敲低选定的差异circRNA_05805,并将其分成circRNA_05805过表达组(转染circRNA_05805过表达质粒)、circRNA_05805低表达组(转染circRNA_05805抑制质粒)及对照组(PBS),CCK8检测各组BMSCs增值能力,ALP、茜素红检测成骨分化能力,RT-qPCR法和Western blot法检测OCN、Runx2 mRNA及蛋白的表达。 结果 高通量测序结果显示,下调的circRNAs中,假手术组与去卵巢组circRNA_05805的差异倍数较高(log2FC=-6.995,P<0.01);RT-qPCR检测结果显示,去卵巢组骨组织中circRNA_05805表达量低于假手术组,与高通量测序结果一致。细胞实验结果显示,circRNA_05805过表达组BMSCs增殖能力、ALP活性、矿化结节形成能力及成骨相关因子OCN、Runx2的mRNA及蛋白表达高于circRNA_05805低表达组及对照组(P<0.05);circRNA_05805低表达组BMSCs增殖能力、ALP活性、矿化结节形成能力及成骨相关因子OCN、Runx2的mRNA及蛋白表达低于对照组(P<0.05)。 结论 circRNA_05805在大鼠骨质疏松模型中低表达,升高其表达能促进BMSCs成骨分化,可能是骨质疏松治疗的新靶点。

[关键词] 骨质疏松;高通量测序;环状 RNA;circRNA-05805;Akt3;骨髓间充质干细胞

骨质疏松(osteoporosis,OP)是以骨量低下、骨微结构进行性破坏为特征的全身性疾病,全球发病超2亿人,严重威胁公众健康[1]。目前常用的抗OP药物疗效仍待进一步提高[2-3]。因此,深入研究OP分子调控机制,挖掘新型治疗靶点,具有重要临床价值。

环状RNA(circular RNA,circRNA)是前体mRNA经反向剪接作用生成的闭合环形非编码RNA分子,在进化过程中展现了高度的稳定性、组织特异性及保守性。近年来,随着对非编码RNA研究的不断深入,circRNA在骨代谢调控中的关键作用逐渐受到关注[4-5]。circRNA作为OP发生和发展的核心调控因子,其潜在的治疗价值正逐步凸显。

本研究构建大鼠OP模型,利用高通量测序技术筛选骨组织中差异表达的circRNA,并通过细胞实验验证其对骨髓间充质干细胞(bone marrow mesenchymal stem cells,BMSCs)成骨分化的影响,旨在探讨circRNA在OP中的作用及作为治疗靶点的潜力,为OP治疗提供实验依据。

1 材料与方法

1.1 实验时间及地点

该实验于2024年12月至2025年5月在新疆医科大学的动物实验中心进行。

1.2 材料

1.2.1 实验动物

12只8周龄SPF级雌性SD大鼠,体质量250~300 g,由新疆医科大学动物实验中心提供[生产许可证:SYXK(新)2023-0001,使用许可证号:SYXK(新)2023-0004,动物合格证号:062773]。本研究经新疆医科大学动物实验医学伦理委员会批准(IACUC-JT-20240424-39)。

1.2.2 实验试剂与仪器

mirVana™ miRNA Isolation Kit(美国Ambion公司,货号:AM1561);TruSeq Stranded Total RNA with Ribo-Zero Gold试剂盒(美国Illumina公司,货号:RS-122-2301);5X All-In-One RT MasterMix(加拿大Applied Biological Materials Inc公司,货号:G592);BlasTaq 2×qPCR Master Mix(加拿大Applied Biological Materials Inc公司,货号:G891);冻存BMSCs(武汉尚恩生物技术有限公司,货号:HS-bMSC-01);Lipofectamine 3000 试剂(美国Invitrogen公司,货号:L3000015);CCK8试剂(美国TargetMol公司,货号:C0038);ALP检测试剂盒(上海吉至生化科技有限公司,货号:BC0280);茜素红S(美国Sigma公司,货号:A5533)。Illumina NovaSeq X Plus 测序平台(美国Illumina公司,型号:NovaSeq X Plus-10b);倒置显微镜(日本Olympus公司,型号:CKX53);酶标仪(美国Bio-Rad公司,型号:Model680)。

1.3 实验方法

1.3.1 OP大鼠模型的建立及标本收集

健康雌性SD大鼠12只,饲养于SPF级鼠室,采用随机数字表法将其分为假手术组和去卵巢组,每组6只。尾静脉注射戊巴比妥钠(30 mg/kg)麻醉,结扎输卵管后完整切除双侧卵巢[6]。假手术组仅暴露肾周脂肪,不行卵巢切除。术后12周,安乐死大鼠,右侧股骨行micro-CT检查及组织学染色;左侧股骨液氮速冻,行RNA提取及检测,各样本均设3个生物学重复,确保结果可靠。

1.3.2 骨组织circRNA高通量测序与分析

取两组大鼠各3只,采用mirVana™ miRNA Isolation Kit提取左股骨髁总RNA,由上海欧易生物医学科技有限公司行PE150测序,DEGseq筛选差异circRNA,ClusterProfiler进行基因本体(gene ontology,GO)、京都基因和基因组数据库(Kyoto Encyclopedia of Genes and Genomes,KEGG)富集分析。

1.3.3 细胞实验

1.3.3.1 细胞培养 冻存BMSCs于37 ℃水浴融化,4 ℃、1 000×g(离心半径10 cm)离心5 min,弃上清;加10%FBS、1%双抗的α-MEM培养基;按5×103个/cm2接种至培养瓶,37 ℃、5%CO2培养;细胞融合度达80%~90%时传代,取第3代的BMSCs用于后续实验。

1.3.3.2 细胞转染与分组 取对数生长期BMSCs,采用Lipofectamine 3000将构建的circRNA_05805过表达质粒(circRNA_05805过表达组)、circRNA_05805过表达阴性对照质粒(circRNA_05805过表达阴性对照组)、circRNA_05805抑制质粒(circRNA_05805低表达组)及circRNA抑制阴性对照质粒(circRNA_05805低表达阴性对照组)转染细胞。同时设置对照组(PBS),48 h后,RT-qPCR法评估转染效率。随后将BMSCs分为circRNA_05805过表达组、circRNA_05805低表达组及对照组。

1.3.3.3 BMSCs功能检测 将转染成功的各组BMSCs制备为单细胞悬液,接种于96孔板,每组5个复孔。37 ℃、5%CO2培养,于0、48、72 h行CCK8检测,酶标仪分析450 nm处光密度(optical density,OD)值,比较细胞增殖能力。实验独立重复3次。

ALP活性检测:取转染合格的BMSCs接种于12孔培养板,每组3个复孔,加入成骨诱导液,按ALP试剂盒说明书检测细胞活性,利用Image J软件定量分析。实验独立重复3次。

矿化结节染色:转染后的BMSCs接种于6孔培养板,每组3个复孔,加成骨诱导液,培养21 d,茜素红S染色,倒置显微镜观察,Image J软件定量矿化结节,分析成骨能力。实验独立重复3次。

成骨相关基因表达:转染后7 d,RT-qPCR法检测OCN、Runx2的mRNA相对表达量,Western blot法检测其蛋白表达,实验独立重复3次。引物序列见表1,以GAPDH为内参。

表1 OCN、Runx2引物序列

基因名称引物序列(5’→3’)引物大小(bp)OCN正向引物:CTGAAAGCCCACAGATACCAG 21反向引物:TGGAGAGGGTTGTTAGTGTGTC 22 Runx2正向引物:ATGCTTCATTCGCCTCACAA 20反向引物:GCACTCACTGACTCGGTTGG 20 GAPDH正向引物:AGGTCGGTGTGAACGGATTTG 21反向引物:TGAGGTCAATGAGGGGATCTT 21

1.4 统计学方法

采用SPSS 27.0统计学软件进行数据分析。计量资料采用均数±标准差表示,比较采用独立样本t检验;多组间比较采用单因素方差分析,两两比较采用LSD-t检验。以P<0.05为差异有统计学意义。

2 结果

2.1 大鼠OP模型成功构建

2.1.1 假手术组与去卵巢组Micro-CT检查

去卵巢组股骨近端骨密度、骨体积分数、骨小梁厚度低于假手术组(P<0.01);骨表面积/体积比高于假手术组(P<0.01)。见图1。

图1 假手术组与去卵巢组Micro-CT检查(n=6)

2.1.2 HE染色

假手术组大鼠骨小梁排列整齐、致密,结构完整,骨小梁间隙小;去卵巢组大鼠骨小梁稀疏、变细,排列紊乱,连续性中断,骨小梁间隙明显增大(图2),提示OP模型构建成功。

图2 假手术组与去卵巢组骨组织HE染色(×40)

2.2 骨组织差异circRNA筛选与验证

2.2.1 高通量测序结果

根据Illumina测序结果,去卵巢组中显著差异表达的circRNAs共1 621个,上调808个,下调813个;火山图、聚类热图均显示,差异circRNAs在假手术组与去卵巢组中表达异质性显著(图3A、B)。在下调的circRNA中,假手术组与去卵巢组circRNA_05805的差异倍数较高(log2FC=-6.995,P<0.01),其宿主基因Akt3的GO富集分析结果显示其可参与“细胞功能调控”等过程(图3C)。KEGG富集分析结果显示主要富集在“细胞黏附、细胞衰老、破骨细胞分化和MAPK信号通路”(图3D),故选取circRNA_05805进行后续研究。

图3 高通量测序结果(n=3)

2.2.2 RT-qPCR验证

设计并合成circRNA_05805引物:Akt3正向引物为5’-GATGCAGCTACCATGAAG-3’,Akt3反向引物为 5’-CTTTCCAGAATGTAGATAGTCC-3’。RT-qPCR结果显示,去卵巢组骨组织中circRNA_05805表达量低于假手术组(0.52±0.08 vs.1.03±0.15,t=5.921,P<0.05),与高通量测序结果一致。

2.3 circRNA_05805功能验证

对照组、circRNA_05805过表达阴性对照组、circRNA_05805低表达阴性对照组circRNA_05805表达量比较,差异无统计学意义(P>0.05);circRNA_05805过表达组circRNA_05805表达量高于circRNA_05805过表达阴性对照组(P<0.01);circRNA_05805低表达组circRNA_05805表达量低于circRNA_05805低表达阴性对照组(P<0.01);转染及敲低效率符合预期。见图4。

图4 各组circRNA_05805表达水平(n=3)

2.4 circRNA_05805对BMSCs成骨分化的影响

2.4.1 细胞增殖

circRNA_05805过表达组细胞在72 h的OD值高于circRNA_05805低表达组和对照组,circRNA_05805低表达组低于对照组(P<0.05)。提示过表达circRNA_05805可促进BMSCs增殖,敲低则抑制其增殖。见图5。

图5 各组细胞CCK8的OD值(n=3)

2.4.2 ALP染色

circRNA_05805过表达组在第7、21天着色显著(图6A),定量分析显示circRNA_05805过表达组ALP活性高于circRNA_05805低表达组、对照组;circRNA_05805低表达组ALP活性低于对照组(P<0.01),见图6B,提示过表达circRNA_05805可增强BMSCs成骨能力,而敲低后BMSCs成骨能力降低。

图6 ALP染色(n=3)

2.4.3 茜素红染色

circRNA_05805过表达组矿化结节数量在第7、21天高于circRNA_05805低表达组、对照组;circRNA_05805低表达组矿化结节数量在第7、21天低于对照组(P<0.05),见图7A、B。进一步提示过表达circRNA_05805后BMSCs成骨能力增强。

图7 茜素红染色(n=3)

2.4.4 RT-qPCR法及Western blot法检测成骨相关因子

circRNA_05805过表达组OCN、Runx2的mRNA及蛋白表达高于circRNA_05805低表达组、对照组;circRNA_05805低表达组OCN、Runx2的mRNA及蛋白表达低于对照组(P<0.05)。见图8A~E。

图8 成骨相关因子表达(n=3)

3 讨论

circRNAs在OP发病中发挥关键调控作用,已成为目前研究的热点[7-9]。与线性RNA比较,circRNA在细胞内具有较高稳定性,为其成为疾病诊断标志物和潜在治疗靶点奠定了基础[10-12]。已有研究表明,多个circRNAs(如circ_0134944、circ_0021739、circ_0006859等)在OP患者外周血、单核细胞及血清外泌体中异常表达,可通过吸附microRNA、结合功能蛋白等途径调控骨代谢[13-16]。本研究通过高通量测序发现circRNA_05805在去卵巢OP大鼠骨组织中显著低表达,上调其表达可促进BMSCs成骨分化。其宿主基因AKT3主要富集于细胞衰老、破骨分化及MAPK信号通路,而MAPK通路是调控成骨分化的经典通路。这一结果提示circRNA_05805可能通过调控宿主基因相关通路发挥骨代谢作用。该发现既契合现有circRNA调控骨代谢的共性机制,又因靶向AKT3相关通路展现出独特性,进一步丰富了OP相关circRNA调控网络。

BMSCs是维持骨代谢平衡的关键细胞,其自我更新能力减弱、成骨分化潜能降低是OP骨丢失的核心机制[17-19]。不同于既往多以外周血或外泌体为研究对象,本研究以股骨远端骨组织为靶点,更直接反映了目标circRNA在骨微环境中的生理功能,提升了结论可靠性。细胞实验显示,过表达circRNA_05805可显著增强BMSCs增殖活性,升高ALP活性与矿化结节形成能力,上调OCN、Runx2等成骨关键因子,敲低则产生相反效应,提示circRNA_05805可能作为重要分子参与BMSCs成骨分化过程,但其具体作用机制仍待阐明。

本研究存在一定的局限性:功能验证仅在细胞水平,缺乏体内实验;未探索其他具人源同源序列的circRNA,难以构建完整调控网络。今后将开展动物体内实验,阐明其ceRNA机制,扩大研究模型并解析多circRNA协同网络,为OP靶向干预提供理论依据。

4 小结

circRNA_05805在大鼠OP模型中低表达,过表达circRNA_05805可促进BMSCs成骨分化;抑制circRNA_05805则呈现相反效应。本研究结果揭示circRNA_05805可能是OP治疗的新靶点。

利益冲突声明:所有作者均声明不存在利益冲突。

[参考文献]

[1]Fuggle N,Laslop A,Rizzoli R,et al. Treatment of osteoporosis and osteoarthritis in the oldest old [J]. Drugs,2025,85(3):343-360.

[2]Khosla S,Hofbauer L C. Osteoporosis treatment:recent developments and ongoing challenges [J]. Lancet Diabetes Endo,2017,5(11):898-907.

[3]Wang W,Azar T,Tseng W J,et al. Distinct responses of modeling-and remodeling-based bone formation to the discontinuation of intermittent parathyroid hormone treatment in ovariectomized rats [J]. J Bone Miner Res,2022,37(11):2215-2225.

[4]Zhang L,Xu Y,Liu N,et al. CircRNA_1809 promotes the osteogenic differentiation of bone marrow mesenchymal stem cells through miR-370-3p [J]. Sci Rep,2025,15(1):19950.

[5]Fang S,Cao D,Wu Z,et al. Circ_0027885 sponges miR-203-3p to regulate RUNX2 expression and alleviates osteoporosis progression [J]. BMC Musculoskelet Disord,2024,25(1):5.

[6]吴梦玲,张齐娟. 基于Nrf2/ PINK1通路探讨电针联合阿仑膦酸钠对绝经后骨质疏松症大鼠线粒体自噬的影响[J].中国医药导报,2025,22(15):46-52.

[7]Xu F,Xiao Q,Du W W,et al. CircRNA:functions,applications and prospects [J]. Biomolecules,2024,14(12):1503.

[8]Li J,Guo S,Sun Q,et al. Bioinformatics screening and clinical validation of CircRNA and related miRNA in male osteoporosis [J]. BMC Musculoskelet Disord,2025,26(1):117.

[9]Qiu D,Yan B,Xue H,et al. Perspectives of exosomal ncRNAs in the treatment of bone metabolic diseases:focusing on osteoporosis,osteoarthritis,and rheumatoid arthritis [J]. Exp Cell Res,2025,446(2):114457.

[10]毕晶晶,余明阳,李诚. 环状 RNA 在脊髓损伤修复的调控机制及其治疗潜力的研究进展[J]. 中国医药导报,2025,22(14):87-91.

[11]王群,孙雨欣,栾婷,等. circRNA在膀胱癌顺铂耐药中的研究现状及展望[J]. 中国医药导报,2023,20(34):65-68.

[12]Moura S R,Fernandes M J,Santos S G,et al. Circular RNAs:promising targets in osteoporosis [J]. Curr Osteoporos Rep,2023,21(3):289-302.

[13]Yang W,Zhang W,Li F,et al. Dysregulation of circRNA-0076906 and circRNA-0134944 is correlated with susceptibility to osteoporosis and osteoporotic fracture in postmenopausal females from the chinese han population [J]. Pharmgenomics Pers Med,2023,16:183-194.

[14]Guan J,Gan L,Jin D,et al. Overexpression of circ_0021739 in peripheral blood mononuclear cells in women with postmenopausal osteoporosis is associated with reduced expression of microRNA-194-5p in osteoclasts [J]. Med Sci Monit,2021,27,e929170.

[15]Zhi F,Ding Y,Wang R,et al. Exosomal hsa_circ_0006859 is a potential biomarker for postmenopausal osteoporosis and enhances adipogenic versus osteogenic differentiation in human bone marrow mesenchymal stem cells by sponging miR-431-5p [J]. Stem Cell Res,2021(1):157.

[16]Gargano G,Pagano S M,Maffulli N. Circular RNAs in the management of human osteoporosis [J]. Br Med Bull,2025,153(1):ldae024.

[17]Wu S,Ohba S,Matsushita Y. Single-cell RNA-sequencing reveals the skeletal cellular dynamics in bone repair and osteoporosis [J]. Int J Mol Sci,2023,24(12):9814.

[18]Luo Z,Wei W,Qiu D,et al. Rejuvenation of BMSCs senescence by pharmacological enhancement of TFEB-mediated autophagy alleviates aged-related bone loss and extends lifespan in middle aged mice [J]. Bone Res,2024,12(1):45.

[19]Zhao J,Chen A,Wang R,et al. Bmi-1 epigenetically orchestrates osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells to delay bone aging [J]. Adv Sci(Weinh),2024,11(46):e2404518.

Study on the screening of differentially expressed circRNA in osteoporotic rats by high-throughput sequencing and the functional validation of the circRNA

HUANG Huan SUN Rongxin ZHANG Lei SHI Yihan WU Ping

Department of Joint Surgery, the Sixth Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi 830002, China

[Abstract] Objective To screen for differentially expressed circular RNAs (circRNAs) in the rat models of osteoporosis,and to explore the role of circRNAs in the pathogenesis of osteoporosis and their potential as therapeutic targets. Methods Twelve eight-week-old SPF female SD rats were divided into sham operation group and bilateral ovariectomy group using the random number table method, with six rats in each group. After 12 weeks of modeling, the femoral bone tissue was collected and high-throughput sequencing was used to screen for differentially expressed circRNAs. The selected differentially expressed circRNA_05805 was overexpressed and knocked down in bone marrow mesenchymal stem cells(BMSCs), and they were divided into circRNA_05805 overexpression group (transfected with the circRNA_05805 overexpression plasmid) , circRNA_05805 low-expression group (transfected with the circRNA_05805 inhibitory plasmid)and control group (PBS). The proliferation ability of BMSCs in each group was detected by CCK8 assay. The osteogenic differentiation ability was detected by ALP and alizarin red staining. The expressions of OCN and Runx2 mRNA and proteins were detected by RT-qPCR and Western blot. Results The results of high-throughput sequencing showed that among the down-regulated circRNAs, the difference ratio of circRNA_05805 between the sham operation group and the bilateral ovariectomy group was relatively high (log2FC =-6.995, P<0.01). The RT-qPCR detect results showed that the expression level of circRNA_05805 in the bone tissue of the bilateral ovariectomy group was lower than that of the sham operation group, which was consistent with the results of high-throughput sequencing. The results of the cell experiments showed that the proliferation ability, ALP activity, mineralization nodule formation ability, and mRNA and protein expressions of osteogenic-related factors OCN and Runx2 in the circRNA_05805 overexpression group of BM-SCs were higher than those in the circRNA_05805 low-expression group and the control group (P<0.05). The proliferation ability, ALP activity, mineralization nodule formation ability, as well as the mRNA and protein expressions of osteogenic-related factors OCN and Runx2 in the circRNA_05805 low-expression group of BMSCs were all lower than those in the control group (P<0.05). Conclusion The circRNA_05805 is expressed at a low level in the rat osteoporosis model. Increasing its expression can promote the osteogenic differentiation of BMSCs, and this might be a new target for the treatment of osteoporosis.

[Key words] Osteoporosis; High-throughput sequencing; Circular RNA; circRNA-05805; Akt3; Bone marrow mesenchymal stem cells

[中图分类号] R363.2

[文献标识码] A

[文章编号] 1673-7210(2026)09(b)-0036-09

DOI:10.20047/j.issn1673-7210.25111817

[基金项目] 新疆维吾尔自治区卫生健康保健科研专项项目(BH202431)。

[通信作者] 吴萍(1973.2-),女,副主任护师,主要从事骨科临床护理及骨代谢基础研究工作。

(收稿日期:2025-11-21)

(修回日期:2026-04-29)

X